Diagnostic equivalence of an N-terminal pro-brain natriuretic peptide point-of-care test to the laboratory method in patients with heart failure and in reference populations

Point of Care

Volumn 9, Issue 2, 2010, Pages 91-97

  Schäfer, Markus ^a   Bröker, Hans Joachim ^a   Luchner, Andreas ^b   Jungbauer, Carsten ^b   Zugck, Christian ^c   Mitrovic, Veselin ^d   Willenbrock, Roland ^e   Flieger, Robert R ^e   Wittmer, Bret A ^f   Graves, Mark W ^g   Fluder, Kerstin ^h   Zerback, Rainer ^h  

^a Diakonissenkrankenhaus Kassel   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d KERCKHOFF HEART CENTER   (Germany)

^e Krankenhaus St Elisabeth und St Barbara   (Germany)

^f Commonwealth Biomedical Research LLC ^*  (United States)

^g Welborn Clinic   (United States)

^h ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Congestive heart failure; Congestive heart failure dysfunction; Diagnostic sensitivity; Halofuginone; NT proBNP; Point of care testing; Sensitivity

Indexed keywords

EID: 77953089680     PISSN: 1533029X     EISSN: 15330303     Source Type: Journal    
DOI: 10.1097/POC.0b013e3181d9d93a     Document Type: Article

References (15)

1. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208-225.
2. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 2148-2159.
3. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-2442.
4. Zugck C, Nelles M, Katus HA, et al. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clin Chem Lab Med. 2006;44:1269-1277.
5. Bertsch T, Dikkeschei B, Gurr E, et al. Development and calibration of a new point-of-care test for the determination of NT-proBNP in whole blood. Clin Lab. 2007;53:423-431.
6. Bertsch T, Chapelle JP, Dempfle CE, et al. Multicentre evaluation of a new point-of-care system for the determination of cardiac and thromboembolic markers. Clin Lab. 2010;56:37-49.
7. Yeo KTJ, Wu AHB, Apple FS, et al. Multicentre analytical evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003;338:107-115.
8. Collinson PO, Barnes SC, Gaze DC, et al. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail. 2004;6: 365-368.
9. Sokoll LJ, Baum H, Collinson PO, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med. 2004;42:965-972.
10. Thackray SD, Witte K, Ghosh J, et al. N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population. Eur Heart J. 2006;27:447-453.
11. Wu AHB, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628-631.
12. Gustafsson F, Steensgaard-Hansen F, et al. Diagnostic and prognostic performance of N-terminal proBNP in primary care patients with suspected heart failure. J Card Fail. 2005;11(suppl 5): S15-S20.
13. Collinson PO, Gaze DC. Biomarkers of cardiovascular damage and dysfunctionVan overview. Heart Lung Circ. 2007;16:S71-S82.
14. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-337.
15. Hildebrandt P, Gaze D, Rosenberg J, et al. The international collaborative study of N-terminal pro B type natriuretic peptide NTproBNP in primary care (ICON-PC)Va preliminary analysis. Eur Heart J. 2007;28:306.